Company / SG&A Expense
Upstream Bio, Inc. SG&A Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$26.4M
FY2025
5-year range
$10.7M / $26.4M
FY2023-FY2025
Trend
+146.9%
vs FY2024
Sector context
#191 of 213
Health Care
What the data says
Among 213 Health Care companies, Upstream Bio, Inc. is in the top 10% for sg&a expense. Increased from $11M to $26M over the past 2 years.
Based on SEC 10-K filings.
$26M in FY2025.
Increased from $11M to $26M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 213This company $26.4M Sector average $722.3M
▼
-96.3% below sector average
Key checks
Key Insights
- In FY2025, sg&a expense increased 146.9% year-over-year.
- Ranks #191 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.68 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.4M | +146.9% |
| FY2024 | $10.7M | +0.0% |
| FY2023 | $10.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026